Raymond James & Associates Sells 10,059 Shares of Agilent Technologies, Inc. (NYSE:A)

Raymond James & Associates trimmed its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 7.8% in the second quarter, Holdings Channel.com reports. The firm owned 118,388 shares of the medical research company’s stock after selling 10,059 shares during the quarter. Raymond James & Associates’ holdings in Agilent Technologies were worth $15,347,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Quantbot Technologies LP acquired a new stake in shares of Agilent Technologies during the first quarter worth $938,000. Cetera Investment Advisers lifted its holdings in shares of Agilent Technologies by 953.3% in the first quarter. Cetera Investment Advisers now owns 32,694 shares of the medical research company’s stock valued at $4,757,000 after purchasing an additional 29,590 shares in the last quarter. UBS Group AG boosted its position in shares of Agilent Technologies by 84.5% during the fourth quarter. UBS Group AG now owns 325,695 shares of the medical research company’s stock worth $45,281,000 after buying an additional 149,159 shares during the period. TD Asset Management Inc grew its holdings in shares of Agilent Technologies by 27.1% during the fourth quarter. TD Asset Management Inc now owns 1,609,420 shares of the medical research company’s stock worth $223,758,000 after buying an additional 343,175 shares in the last quarter. Finally, iA Global Asset Management Inc. raised its position in Agilent Technologies by 26.2% in the 1st quarter. iA Global Asset Management Inc. now owns 21,770 shares of the medical research company’s stock valued at $3,168,000 after buying an additional 4,523 shares during the last quarter. 87.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Barclays upped their price target on Agilent Technologies from $125.00 to $135.00 and gave the stock an “underweight” rating in a research report on Friday. Stifel Nicolaus lowered their price target on shares of Agilent Technologies from $163.00 to $151.00 and set a “buy” rating on the stock in a research note on Thursday, May 30th. Bank of America increased their price objective on shares of Agilent Technologies from $140.00 to $147.00 and gave the stock a “neutral” rating in a research note on Thursday. Evercore ISI lifted their target price on Agilent Technologies from $130.00 to $135.00 and gave the company an “in-line” rating in a research report on Thursday. Finally, Robert W. Baird reduced their price target on Agilent Technologies from $147.00 to $136.00 and set an “outperform” rating for the company in a research report on Thursday, May 30th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $140.80.

Agilent Technologies Trading Up 0.4 %

A stock opened at $140.77 on Friday. Agilent Technologies, Inc. has a one year low of $96.80 and a one year high of $155.35. The stock has a market cap of $41.07 billion, a price-to-earnings ratio of 33.28, a price-to-earnings-growth ratio of 4.86 and a beta of 1.05. The company has a fifty day moving average price of $134.16 and a two-hundred day moving average price of $138.54. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.15 and a quick ratio of 1.64.

Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, August 21st. The medical research company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.26 by $0.06. The business had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. Agilent Technologies had a net margin of 18.84% and a return on equity of 26.25%. Agilent Technologies’s revenue was down 5.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.43 EPS. Equities analysts anticipate that Agilent Technologies, Inc. will post 5.24 EPS for the current year.

Insider Transactions at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $130.00, for a total transaction of $254,540.00. Following the transaction, the chief executive officer now owns 25,185 shares in the company, valued at $3,274,050. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $130.00, for a total value of $254,540.00. Following the transaction, the chief executive officer now directly owns 25,185 shares in the company, valued at $3,274,050. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Dominique Grau sold 15,000 shares of Agilent Technologies stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $133.28, for a total transaction of $1,999,200.00. Following the completion of the sale, the senior vice president now owns 49,486 shares of the company’s stock, valued at approximately $6,595,494.08. The disclosure for this sale can be found here. Insiders sold a total of 20,874 shares of company stock worth $2,811,770 over the last quarter. Company insiders own 0.33% of the company’s stock.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.